NASDAQ:NVIV

InVivo Therapeutics - NVIV Stock Forecast, Price & News

$9.55

+1.44 (+17.76%)

(As of 08/15/2022 02:56 PM ET)

Add

Compare

Today's Range: $8.40
▼
$10.43
50-Day Range: $3.75
▼
$8.96
52-Week Range: $3.50
▼
$20.23

Volume: 5,425 shs
Average Volume: 294,793 shs
Market Capitalization: $13.28 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About InVivo Therapeutics (NASDAQ:NVIV) Stock

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on InVivo Therapeutics in a report on Tuesday, August 9th. They issued a "sell" rating for the company.

InVivo Therapeutics Stock Performance

Shares of NVIV Stock opened at $8.11 on Monday. InVivo Therapeutics has a fifty-two week low of $3.50 and a fifty-two week high of $20.23. The business has a fifty day simple moving average of $4.65 and a 200-day simple moving average of $6.17.

Receive NVIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVIV Stock News Headlines

August 9, 2022 | americanbankingnews.com

InVivo Therapeutics (NASDAQ:NVIV) Now Covered by Analysts at StockNews.com

August 4, 2022 | americanbankingnews.com

InVivo Therapeutics (NASDAQ:NVIV) Earns Sell Rating from Analysts at StockNews.com

August 3, 2022 | americanbankingnews.com

Contrasting InVivo Therapeutics (NASDAQ:NVIV) & Artivion (NYSE:AORT)

July 26, 2022 | americanbankingnews.com

InVivo Therapeutics (NASDAQ:NVIV) Coverage Initiated by Analysts at StockNews.com

July 13, 2022 | finance.yahoo.com

InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel

June 8, 2022 | finance.yahoo.com

InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery

June 2, 2022 | finance.yahoo.com

InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study

April 18, 2022 | finance.yahoo.com

Why Are InVivo Therapeutics Shares Trading Lower During Premarket Monday?

April 15, 2022 | nasdaq.com

Why InVivo Therapeutics Stock Falling?

April 14, 2022 | marketwatch.com

InVivo Therapeutics Announces 1-for-25 Reverse Stock Split

April 14, 2022 | finance.yahoo.com

InVivo Therapeutics stock sinks after 1-for-25 reverse stock split announced

April 14, 2022 | seekingalpha.com

InVivo Therapeutics slumps 7% on 1-for-25 reverse stock split

February 8, 2022 | finanznachrichten.de

Sidekick Health: DTx leader Sidekick announces key C-level hires in move to accelerate U.S. market growth

February 8, 2022 | finance.yahoo.com

DTx leader Sidekick announces key C-level hires in move to accelerate U.S. market growth

January 30, 2022 | fool.com

InVivo Therapeutics Holdings(NVIV)

January 6, 2022 | finance.yahoo.com

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference

December 29, 2021 | nasdaq.com

InVivo Therapeutics Holdings Corp Shares Fall 1.4% Below Previous 52-Week Low - Market Mover

December 29, 2021 | nasdaq.com

InVivo Therapeutics Holdings Corp Shares Close the Day 11.0% Lower - Daily Wrap

September 9, 2021 | finance.yahoo.com

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference

September 8, 2021 | finance.yahoo.com

InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study

August 7, 2021 | nasdaq.com

InVivo Therapeutics Holdings Corp Common Stock (NVIV)

July 19, 2021 | finance.yahoo.com

InVivo Therapeutics Holdings (NASDAQ:NVIV) Is In A Good Position To Deliver On Growth Plans

July 13, 2021 | uk.finance.yahoo.com

InVivo Therapeutics Announces FDA Acceptance of Preclinical Module in Support of Company’s Complete HDE Submission

July 13, 2021 | marketwatch.com

InVivo Therapeutics Up After FDA Accepts Preclinical Part of Application

July 6, 2021 | finance.yahoo.com

InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NVIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVIV Company Calendar

Last Earnings: 5/13/2020
Today: 8/15/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NVIV
CUSIP: N/A
CIK: 1292519
Web: www.invivotherapeutics.com
Phone: (617) 863-5500
Fax: N/A
Employees: 6
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($7.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,900,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -63.73%
Return on Assets: -53.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.64
Quick Ratio: 5.64

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $13.22 per share
Price / Book: 0.72

Miscellaneous

Outstanding Shares: 1,391,000
Free Float: 1,390,000
Market Cap: $13.28 million
Optionable: Not Optionable
Beta: 1.30

Key Executives

Dr. Richard M. Toselli (Age 64)
Pres, CEO, Chief Medical Officer & Director
Comp: $940.27k
Mr. Richard C. Christopher (Age 52)
CFO & Treasurer
Comp: $628.2k
Dr. Robert S. Langer Jr. (Age 73)
Ph.D., Sc.D., SCD, Co-Founder & Member of Scientific Advisory Board
Dr. Joseph Philip Vacanti (Age 73)
Co-Founder
Mr. Jerome Gangitano
Sr. VP of Operations
Ms. Heather Hamel
VP of Legal Affairs & Bus. Devel. and Corp. Sec.
Dr. Louis Vaickus FACP (Age 69)
M.D., Consultant

Key Competitors

View All Competitors

NVIV Stock - Frequently Asked Questions

How have NVIV shares performed in 2022?: InVivo Therapeutics' stock was trading at $11.4025 at the beginning of the year. Since then, NVIV stock has decreased by 28.9% and is now trading at $8.11.
View the best growth stocks for 2022 here.
How were InVivo Therapeutics' earnings last quarter?: InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) announced its earnings results on Wednesday, May, 13th. The biotechnology company reported ($61.75) EPS for the quarter.
When did InVivo Therapeutics' stock split?: Shares of InVivo Therapeutics reverse split before market open on Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of InVivo Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other InVivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), iShares Preferred and Income Securities ETF (PFF), Verastem (VSTM), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), Apollo Investment (AINV), IVERIC bio (OPHT), OPKO Health (OPK) and Cardiff Oncology (TROV).

What is InVivo Therapeutics' stock symbol?: InVivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."
How do I buy shares of InVivo Therapeutics?: Shares of NVIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is InVivo Therapeutics' stock price today?: One share of NVIV stock can currently be purchased for approximately $8.11.
How much money does InVivo Therapeutics make?: InVivo Therapeutics (NASDAQ:NVIV) has a market capitalization of $11.28 million. The biotechnology company earns $-9,900,000.00 in net income (profit) each year or ($7.69) on an earnings per share basis.
How can I contact InVivo Therapeutics?: InVivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The official website for the company is www.invivotherapeutics.com. The biotechnology company can be reached via phone at (617) 863-5500 or via email at info@invivotherapeutics.com.

This page (NASDAQ:NVIV) was last updated on 8/15/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources